Doctor Clay Siegall is the Chairman, President, CEO and co-founder of biotechnology company Seattle Genetics. He holds a doctorate in genetics from George Washington University. Under Clay’s visionary leadership, Seattle Genetics has been on the cutting edge in the development of cancer therapies. Prior to co-founding the company in 1998, he spent 1991 to 1997 working for Bristol-Myers Pharmaceutical Research Institute and worked for the National Cancer Institute, National Institutes of Health from 1998 to 1991. Clay is a published author with more than 70 publications, serves as a member of the Board of Directors of Alder BioPharmaceuticals and also holds 15 patents.
What Will the Future Hold for Seattle Genetics:
The topic of the success of Clay’s company Seattle Genetics was the topic of a recent article featured on Seattle Business. The heart of the research being undertaken at Seattle Genetics revolves around antibodies. The company has been devoting its time studying and manipulating antibodies since its 1998 founding. This research has yielded many revolutionary drugs that attack cancer cells. The strategy of focussing on antibodies has Seattle Genetics well positioned to enter the business world’s major leagues. The Seattle based company now has a market value of nearly $10 billion and fields an employee based of 900. It is the largest biotech company in the state of Washington but Clay is not satisfied with stopping there. Clay and his revolutionary company are aspiring to move up into the category of big pharma. To aid in accomplishing this goal, the company is investing heavily in continued research, marketing and expansion of the employee base. 200 more employees are expected to be added to the roster. Seattle Genetics is developing the drug Adcetris, a compound that treats Hodgkin lymphoma. There is a strong feeling within the organization that sales of Adcetris could take off if current tests continue to go as well as they have to date. Clay Siegall has stated that “We are an emerging global, multiproduct, oncology company.”
Clay Siegall Opens Up About His Career:
Clay Siegall recently sat down with Ideamensch to discuss his career, Seattle Genetics and what has made him successful as a businessman. When asked about where the idea for Seattle Genetics started, Clay responds that “Helping patients is the primary focus of Seattle Genetics. Watching my father’s progression with cancer from when I was 19 years old until his death when I was 24 made me acutely aware of the limited tools available to oncologists at the time. I wanted to improve those tools.” Clay believes that an important quality for an entrepreneur to possess is to be constantly trying to learn and to never think that you know everything. He believes the most important strategy that has helped him grow his Seattle Genetics business is that fact that the company collaborates with other industry leaders in the oncology drug field.
Award Winning Career:
Clay Siegall has had a number of prestigious awards bestowed on him over the years in recognition of his important work. The list includes the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year Award.